EP0850067A4 - Method for treating cancers using 6- 3- 1-adamantyl]-4-hydroxyphenyl] - Google Patents

Method for treating cancers using 6- 3- 1-adamantyl]-4-hydroxyphenyl]

Info

Publication number
EP0850067A4
EP0850067A4 EP96924519A EP96924519A EP0850067A4 EP 0850067 A4 EP0850067 A4 EP 0850067A4 EP 96924519 A EP96924519 A EP 96924519A EP 96924519 A EP96924519 A EP 96924519A EP 0850067 A4 EP0850067 A4 EP 0850067A4
Authority
EP
European Patent Office
Prior art keywords
adamantyl
hydroxyphenyl
treating cancers
cancers
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP96924519A
Other languages
German (de)
French (fr)
Other versions
EP0850067A1 (en
Inventor
Joseph A Fontana
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galderma Research and Development SNC
Original Assignee
Centre International de Recherches Dermatologiques Galderma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre International de Recherches Dermatologiques Galderma filed Critical Centre International de Recherches Dermatologiques Galderma
Publication of EP0850067A1 publication Critical patent/EP0850067A1/en
Publication of EP0850067A4 publication Critical patent/EP0850067A4/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP96924519A 1995-07-17 1996-07-17 Method for treating cancers using 6- 3- 1-adamantyl]-4-hydroxyphenyl] Ceased EP0850067A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US601465 1990-10-23
US146595P 1995-07-17 1995-07-17
PCT/US1996/011736 WO1997003682A1 (en) 1995-07-17 1996-07-17 Method for treating cancers using 6-[3-[1-adamantyl]-4-hydroxyphenyl]

Publications (2)

Publication Number Publication Date
EP0850067A1 EP0850067A1 (en) 1998-07-01
EP0850067A4 true EP0850067A4 (en) 1999-12-15

Family

ID=21696159

Family Applications (1)

Application Number Title Priority Date Filing Date
EP96924519A Ceased EP0850067A4 (en) 1995-07-17 1996-07-17 Method for treating cancers using 6- 3- 1-adamantyl]-4-hydroxyphenyl]

Country Status (5)

Country Link
EP (1) EP0850067A4 (en)
JP (1) JP2000506489A (en)
AU (1) AU701790B2 (en)
CA (1) CA2223489A1 (en)
WO (1) WO1997003682A1 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2739557B1 (en) 1995-10-09 1997-11-14 Cird Galderma USE OF A RAR-GAMMA SPECIFIC AGONIST LIGAND
IL127946A0 (en) * 1996-07-08 2000-02-17 Cird Galderma Apoptosis inducing adamantyl derivatives and their usage as anti-cancer agents
US6462064B1 (en) 1996-07-08 2002-10-08 Galderma Research & Development S.N.C. Apoptosis inducing adamantyl derivatives and their usage as anti-cancer agents, especially for cervical cancers and dysplasias
ES2248107T3 (en) 1999-08-31 2006-03-16 Incyte San Diego Incorporated BENCILIDEN-TIAZOLIDINDIONAS AND ANALOGS AND ITS USE IN THE TREATMENT OF DIABETES.
AU2002252227A1 (en) 2001-03-07 2002-09-24 Maxia Pharmaceuticals, Inc. Heterocyclic derivatives for the treatment of cancer and other proliferative diseases
CA2473156A1 (en) 2001-03-08 2002-09-19 Incyte San Diego, Inc. Rxr activating molecules
DE10255861A1 (en) * 2002-11-29 2004-06-17 Axxima Pharmaceuticals Ag Preventing or treating hepatitis C virus infection comprises administering an agent that inhibits or stimulates the activity or production of human gastrointestinal glutathione peroxidase
KR100453877B1 (en) 2001-07-26 2004-10-20 메덱스젠 주식회사 METHOD OF MANUFACTURING Ig-FUSION PROTEINS BY CONCATAMERIZATION, TNFR/Fc FUSION PROTEINS MANUFACTURED BY THE METHOD, DNA CODING THE PROTEINS, VECTORS INCLUDING THE DNA, AND CELLS TRANSFORMED BY THE VECTOR
JP2005513026A (en) 2001-11-15 2005-05-12 インサイト サン ディエゴ インコーポレイテッド Hypercholesterolemia, dyslipidemia and other metabolic disorders; N-substituted heterocycles to treat cancer and other diseases
US7102000B2 (en) 2002-03-08 2006-09-05 Incyte San Diego Inc. Heterocyclic amide derivatives for the treatment of diabetes and other diseases
US7196108B2 (en) 2002-03-08 2007-03-27 Incyte San Diego Inc. Bicyclic heterocycles for the treatment of diabetes and other diseases
AU2003294757A1 (en) * 2002-11-29 2004-06-23 Axxima Pharmaceuticals Ag Formulations useful against hepatitis c virus infections
ES2395401T3 (en) * 2006-03-23 2013-02-12 Tmrc Co., Ltd. kit for cancer therapy and pharmaceutical composition for cancer therapy
WO2007148804A1 (en) * 2006-06-23 2007-12-27 Rohto Pharmaceutical Co., Ltd. Composition capable of promoting the production of hyaluronic acid
EP3301085A1 (en) 2016-09-29 2018-04-04 Biogem S.Ca.R.L. Retinoid derivatives with antitumor activity
WO2022229017A1 (en) 2021-04-27 2022-11-03 Biogem S.C.A R.L. Adamantyl retinoid derivative with anticancer activity

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LU85849A1 (en) * 1985-04-11 1986-11-05 Cird BENZONAPHTHALENIC DERIVATIVES, THEIR PREPARATION PROCESS AND THEIR APPLICATION IN THE PHARMACEUTICAL AND COSMETIC FIELDS

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BOEHM M F ET AL: "DESIGN AND SYNTHESIS OF POTENT RETINOID X RECEPTOR SELECTIVE LIGANDS THAT INDUCE APOPTOSIS IN LEUKEMIA CELLS", JOURNAL OF MEDICINAL CHEMISTRY, vol. 38, no. 16, 4 August 1995 (1995-08-04), pages 3146 - 3155, XP000615461, ISSN: 0022-2623 *
CORBEIL J ET AL: "ANTIPROLIFERATIVE EFFECT OF RETINOID COMPOUNDS ON KAPOSI'S SARCOMA CELLS", JOURNAL OF CLINICAL INVESTIGATION, vol. 93, no. 5, 1 May 1994 (1994-05-01), pages 1981 - 1986, XP000646558, ISSN: 0021-9738 *
SCHADENDORF, D. ET AL.: "Retinoic acid receptor-gamma-selective retinoids exert antiproliverative effects on human melanoma cell growth in vitro", INTERNATIONAL JOURNAL OF ONCOLOGY, vol. 5, no. 6, 1994, pages 1325 - 1331, XP000600684 *
See also references of WO9703682A1 *
SHAO Z -M ET AL: "P53 INDEPENDENT G0/G1 ARREST AND APOPTOSIS INDUCED BY A NOVEL RETINOID IN HUMAN BREAST CANCER CELLS", ONCOGENE, vol. 11, no. 3, 3 August 1995 (1995-08-03), pages 493 - 504, XP000575582, ISSN: 0950-9232 *

Also Published As

Publication number Publication date
WO1997003682A1 (en) 1997-02-06
EP0850067A1 (en) 1998-07-01
AU701790B2 (en) 1999-02-04
JP2000506489A (en) 2000-05-30
CA2223489A1 (en) 1997-02-06
AU6494996A (en) 1997-02-18

Similar Documents

Publication Publication Date Title
IL116242A (en) Irradiation apparatus
PL323178A1 (en) Schirophrenia diagnosin method
EP0850067A4 (en) Method for treating cancers using 6- 3- 1-adamantyl]-4-hydroxyphenyl]
IL125031A0 (en) Method for treating depression
GB9519638D0 (en) Method
GB9518442D0 (en) Method
IL124786A0 (en) Method for treating pain
GB2308522B (en) Redialling method
GB9601976D0 (en) Method
GB9510727D0 (en) Method
ZA971899B (en) Method for treating insomnia
AP9701121A0 (en) Method for prearing streptogramines
GB9511828D0 (en) Method
GB9722553D0 (en) Method
GB2296850B (en) Apparatus for applying designs
AU2198997A (en) Method for treating insomnia
GB9505895D0 (en) Apparatus for treating shoes
GB9513130D0 (en) Treatment method
GB9513129D0 (en) Treatment method
GB9511594D0 (en) Treatment method
HU9400631D0 (en) Process for treating tumors
GB9508498D0 (en) Dying method
GB9514713D0 (en) Method
GB9516528D0 (en) Method
GB9519458D0 (en) Method

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19980202

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 19991104

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20001005

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

RIC1 Information provided on ipc code assigned before grant

Free format text: 7A 61K 31/79 A, 7A 61P 35/02 B, 7A 61P 35/00 B

RTI1 Title (correction)

Free format text: METHOD FOR TREATING BREAST CANCER AND LEUKEMIA USING 6- (3-(1-ADAMANTYL)-4-HYDROXYPHENYL)-2-NAPHTHALENE CARBOXYLIC ACID

RIC1 Information provided on ipc code assigned before grant

Free format text: 7A 61K 31/79 A, 7A 61P 35/02 B, 7A 61P 35/00 B

RTI1 Title (correction)

Free format text: 6- (3-(1-ADAMANTYL)-4-HYDROXYPHENYL)-2-NAPHTHALENE CARBOXYLIC ACID AGAINST BREAST CANCER AND LEUKEMIA

RIC1 Information provided on ipc code assigned before grant

Free format text: 7A 61K 31/79 A, 7A 61P 35/02 B, 7A 61P 35/00 B

RTI1 Title (correction)

Free format text: 6- (3-(1-ADAMANTYL)-4-HYDROXYPHENYL)-2-NAPHTHALENE CARBOXYLIC ACID AGAINST BREAST CANCER AND LEUKEMIA

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20020429

RTI1 Title (correction)

Free format text: 6- ??3-??1-ADAMANTYL -4-HYDROXYPHENYL -2-NAPHTHALENE CARBOXYLIC ACID AGAINST BREAST CANCER AND LEUKEMIA